International Congress on the Future of Breast Cancer West

As ongoing research efforts are shifting further into personalized care, Hope S. Rugo, MD, FASCO discusses how pathologic complete response and the predictive value of residual cancer burden scoring are becoming a pivotal end point for the changing triple-negative breast cancer landscape.

Erika P. Hamilton, MD, shares how multidisciplinary collaboration between pathologist and breast oncologists is key to staying abreast of not only the classification-actionable HER2 mutations in metastatic breast cancer but also the evolving definition of expression.

Nicholas P. McAndrew, MD, MSCE, discusses considerations to take when examining the relationship between chemotherapy, ovarian function suppression, and treatment benefits experienced by patients with hormone receptor–positive, HER2-negative breast cancer.

Sara A. Hurvitz, MD, explains when de-escalation therapy can play a role in patients with HER2-positive breast cancer.

Mark Pegram, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

Nicholas P. McAndrew, MD, MSCE, discusses the relationship between chemotherapy and ovarian function suppression in hormone receptor–positive, HER2-negative breast cancer.

Aditya Bardia, MD, MPH, discusses the need for oral selective estrogen receptor degraders in ESR1-mutant, estrogen receptor–positive breast cancer.

Aditya Bardia, MD, MPH, discusses recent and ongoing trials evaluating oral SERDs in estrogen receptor–positive breast cancer, the effect of ESR1 mutations on treatment efficacy, and how the use of ctDNA continues to evolve across the breast cancer space.

Mark D. Pegram, MD, discusses considerations for treatment selection in HER2-positive breast cancer.

Sara A. Hurvitz, MD, highlights that although differences in overall survival and toxicity profile could inform treatment selection with CDK4/6 inhibitors, optimal sequencing with these agents remains uncertain.

Physicians treating patients with HER2-positive metastatic breast cancer have had their share of wins with treatment advances in the past few years.

Neoadjuvant and adjuvant treatment with CDK4/6 inhibitors has shown encouraging preliminary evidence in patients with estrogen receptor–positive, HER2-negative breast cancer, but confirmation of durable benefit is needed in the adjuvant setting before they are brought into routine clinical practice.

Although strategies for treating brain metastases in patients with advanced breast cancer are showing signs of efficacy, new approaches are needed to prevent high-risk, HER2-positive early disease from spreading to the central nervous system.

The advent of gene expression assays has provided predictive insight into chemotherapy benefit that can be combined with prognostic information yielded by gene expression profiling to better target patients with breast cancer who are at higher clinical risk for the use of adjuvant chemotherapy.

Joyce A. O'Shaughnessy, MD, discusses the importance of research regarding the application of DNA repair deficiency in breast cancer, even though it's still in early stages.

Ruth O’Regan, MD, discusses biomarkers of response to CDK4/6 inhibitors in breast cancer.

Debu Tripathy, MD, discusses genomically guided therapy in breast cancer.

Lori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses mechanisms of resistance to endocrine therapy.

Debu Tripathy, MD, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.

Joyce A. O'Shaughnessy, MD, discusses the evolving area of breast cancer subtype-specific cytotoxic agents.